Keep up with the latest developments from Clarus.

Press Releases
Events & Presentations

Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

October 26, 2021

Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA

October 14, 2021

Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 22, 2021

Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies

September 16, 2021

Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 15, 2021

Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies

September 9, 2021

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

July 15, 2021

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer

May 25, 2021

Clarus Therapeutics Defeats Lipocine’s Patent Infringement Lawsuit on Summary Judgment

May 25, 2021

Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming a Publicly Listed Company to Address Unmet Needs of Men and Women Through Development of Androgen and Metabolic Therapies

April 27, 2021

Clarus Therapeutics Presents Positive Safety and Efficacy Data for Jatenzo® (testosterone undecanoate) Oral Capsules, CIII at ENDO 2021, the Endocrine Society's Annual Meeting

March 20, 2021

Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer

February 24, 2021

Clarus Announces JATENZO® (testosterone undecanoate) Capsules, CIII now Covered by Express Scripts

December 7, 2020

Clarus Therapeutics Announces Financing to Support the Commercial Launch and Availability of JATENZO® (testosterone undecanoate) Capsules, CIII for the Treatment of Hypogonadism

March 16, 2020

Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) Capsules, CIII for the Treatment of Hypogonadism

February 10, 2020

Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII

December 11, 2019

Lipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics' JATENZO® Product: Trial Date Set for August 2020

August 26, 2019

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®

August 19, 2019

Clarus Therapeutics Refutes Patent Infringement Complaint

April 3, 2019

Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men

March 27, 2019

Upcoming Events

There are no events

Past Events

Please see the full Prescribing Information for JATENZO, including BOXED WARNING on increases in blood pressure.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

JATENZO^® is a registered trademark of Clarus Therapeutics, Inc.

Keep up with the latest developments from Clarus.

Keep up with the latest developments from Clarus.

Upcoming Events

Past Events

AUA 2021

AACE 2021

ENDO 2021

Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA)

Western Section of the AUA Annual Meeting

North Central Section of the AUA Annual Meeting

Southcentral Section of the AUA Annual Meeting

American Society for Men’s Health

Northeastern Section of the AUA Annual Meeting

New England Section of the AUA Annual Meeting

AUA Live

ENDO Online 2020

AACE 2020